Nasdaq · Healthcare
IONIS PHARMACEUTICALS INC (IONS)
As-reported financials and recent SEC filings for IONIS PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$943.7M
Net income
$-381.4M
Net margin
-40.4%
Diluted EPS
$-2.38
ROE
-78.0%
P/E (TTM)
—
Market cap
$13.42B
Debt / equity
2.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $943.7M | $705.1M | $787.6M | $587.4M | $810.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $-381.7M | $-475.1M | $-353.7M | $-410.2M | $-30.2M |
| Net income | $-381.4M | $-453.9M | $-366.3M | $-269.7M | $-28.6M |
| Diluted EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →1442026-06-26
View on EDGAR →42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →8-K2026-06-24
View on EDGAR →42026-06-16
View on EDGAR →Go deeper on IONS
Search IONIS PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.